BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.6% gain over the past six months, beating the S&P 500 by 11.4 percentage points.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Supernus Pharmaceuticals has almost doubled investors' money over the past five years, yet the stock still screens as cheap on the broad valuation checks. This raises a clear question about how much of the recent merger news and growth outlook is already reflected in the price. Around 90.6% total return over five years suggests Supernus Pharmaceuticals has rewarded patient shareholders without moving into obviously stretched territory. The planned all stock merger with Indivior can support...

SUPN vs. TEVA: Which Stock Is the Better Value Option?

EDRY, OPBK, SUPN, MSBI and NXRT have been added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.

BCAL, SUPN and NXRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 7th, 2026.

Supernus Pharmaceuticals Inc (SUPN) raises full-year guidance on robust GOCOVRI and Qelbree sales, while advancing key CNS pipeline assets.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

Through this merger, the duo will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for.

It's effecting a "merger of equals" with a peer.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) reported second-quarter 2026 results on Monday that fell short of earnings expectations but exceeded revenue forecasts, while also announcing a merger agreement with Indivior Pharmaceuticals (NASDAQ:INDV).

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July’s sharp pullback.

Supernus (SUPN) delivered earnings and revenue surprises of 0.00% and +6.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said Monday that they will merge

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 32.4% year on year to $219.1 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 0.9% above analysts’ estimates. Its GAAP loss of $1.01 per share was significantly below analysts’ consensus estimates.

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Pharmaceuticals recently drew attention after analysts became more optimistic about its upcoming August 4, 2026 earnings report, citing a positive Earnings ESP of 18.52% and the company’s track record of exceeding consensus in its last two quarters. This shift in sentiment highlights how earnings surprise potential can influence perceptions of Supernus’s ability to convert its central nervous system portfolio into stronger financial performance. With analysts pointing to a strong...

Supernus Pharmaceuticals (SUPN) is drawing attention after analysts turned more bullish on its earnings prospects, citing a positive Earnings ESP of 18.52% and a recent pattern of beating consensus estimates. See our latest analysis for Supernus Pharmaceuticals. At a share price of US$46.98, Supernus Pharmaceuticals has seen mixed short term moves, with the share price return up 1.69% over the last day but down 5.03% year to date, while the 1 year total shareholder return of 40.62% points to...

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.